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Abstract
Cancer cells utilize lysosomes for invasion and metastasis. Myeloid Zinc Finger1 (MZF1) is an ErbB2-responsive
transcription factor that promotes invasion of breast cancer cells via upregulation of lysosomal cathepsins B and L.
Here we identify let-7 microRNA, a well-known tumor suppressor in breast cancer, as a direct negative regulator of
MZF1. Analysis of primary breast cancer tissues reveals a gradual upregulation of MZF1 from normal breast epithelium
to invasive ductal carcinoma and a negative correlation between several let-7 family members and MZF1 mRNA,
suggesting that the inverse regulatory relationship between let-7 and MZF1 may play a role in the development of
invasive breast cancer. Furthermore, we show that MZF1 regulates lysosome trafﬁcking in ErbB2-positive breast cancer
cells. In line with this, MZF1 depletion or let-7 expression inhibits invasion-promoting anterograde trafﬁcking of
lysosomes and invasion of ErbB2-expressing MCF7 spheres. The results presented here link MZF1 and let-7 to
lysosomal processes in ErbB2-positive breast cancer cells that in non-cancerous cells have primarily been connected to
the transcription factor EB. Identifying MZF1 and let-7 as regulators of lysosome distribution in invasive breast cancer
cells, uncouples cancer-associated, invasion-promoting lysosomal alterations from normal lysosomal functions and
thus opens up new possibilities for the therapeutic targeting of cancer lysosomes.
Introduction
Lysosomes are membrane-enclosed acidic organelles
responsible for cellular clearance of damaged macro-
molecules and organelles1. In addition to these house-
keeping functions, cancer cells can make effective use of
lysosomes and their degradative enzymes to promote
invasion and metastasis2–4. Malignant transformation and
cancer progression to invasive disease are associated with
altered lysosomal trafﬁcking and increased expression and
secretion of lysosomal cysteine cathepsins B and L2,5–7.
When secreted to extracellular space, cathepsins mod-
ulate the microenvironment by cleaving and activating
other invasion-promoting proteases, such as the uroki-
nase plasminogen activator (uPA) system and matrix
metalloproteases (MMPs), and by inactivating E-cadherin
and CAM adhesion proteins expressed on the cell sur-
face5,8–10. Accordingly, the lack of cathepsin B sig-
niﬁcantly delays and its overexpression further increases
invasion and formation of lung metastases in the highly
metastatic murine mammary tumor virus-polyoma
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middle T antigen (PyMT)-driven mammary cancer in
mice11, 12. Similarly, the ErbB2-induced invasion of
human breast cancer cell spheres in 3-dimensional (3D)
Matrigel cultures depends on the increased expression
and activity of cathepsin B13.
In addition to the increased lysosomal cathepsin activ-
ity, ErbB2-induced invasion of breast and ovarian cancer
cells involves anterograde trafﬁcking of lysosomes: in
response to ErbB2 activation the lysosome distribution
changes from a normal perinuclear or scattered dis-
tribution to the cell periphery13,14. Here they can secrete
their contents, including cathepsin B, by lysosomal exo-
cytosis and induce invasion-promoting intracellular and
extracellular degradation13,15,16. ErbB2-induced cathepsin
B expression is mediated by the transcription factor
MZF1, which binds directly to the ErbB2-inducible
enhancer element in the cathepsin B gene (CTSB)13.
Malignant lysosomal distribution can be reverted by
depletion of ErbB2 or cathepsins B and L. The possible
regulatory role of MZF1 in the lysosome distribution has
not been addressed before. In normal, non-cancerous cells
the transcription factor EB (TFEB) is a master regulator of
lysosomal biogenesis and exocytosis. It increases both
cathepsin B expression and transport of lysosomes to the
cell periphery17,18. TFEB is, however, not involved in the
CTSB upregulation induced by ErbB2 in breast cancer
cells13, suggesting that other transcription factors may
regulate the anterograde trafﬁcking of lysosomes in can-
cer cells.
MiRNAs of the let-7 family are among the miRNAs
whose altered expression is most frequently associated
with cancer19. Let-7 is upregulated during differentiation
of normal cells and tissues20 and downregulated in poorly
differentiated cancer tissues21,22. Its expression is strongly
downregulated or even lost in many highly malignant
cancers including advanced breast cancer21. In breast
cancer-initiating cells, let-7 is one of the most consistently
and signiﬁcantly reduced miRNAs and it regulates all of
their key tumorigenic features21, suggesting that let-7 may
function as a tumor suppressor in breast cancer cells.
Despite the correlation between the loss of let-7 and
breast cancer aggressiveness, the mechanistic link
between let-7 and breast cancer cell invasion and metas-
tasis remains elusive.
Restoring the expression of let-7 family members has
been suggested as a therapeutic tool against aggressive
cancers21,23. In this study, we have used ectopic expres-
sion of let-7e, let-7g, and let-7d as a tool to study the
effect of let-7 upregulation in invasive breast cancer cells.
Here we describe a previously unnoticed link between let-
7 and invasion by demonstrating that let-7e and let-7d can
regulate cancer-induced invasion-promoting anterograde
lysosome distribution in ErbB2-positive breast cancer
cells by directly regulating the level of the oncogenic
transcription factor MZF1.
Results
MZF1 expression is upregulated in human breast cancer
We compared MZF1 protein expression in tissue
microarrays (TMAs) containing 321 samples of normal
breast tissue and different grades of primary breast cancer
by quantitative immunohistochemistry (IHC). MZF1 was
expressed predominantly in the nucleus of both normal
ductal epithelial cells and cancer cells (Fig. 1a). MZF1
expression was increased when comparing normal tissues
to invasive ductal carcinoma (IDC; grades 1–2) (Fig. 1b;
Supplementary Figure S1a). In samples of more advanced
IDC (grades 2–3), the mean MZF1 expression remained
increased when compared with normal breast epithelium
samples (Fig. 1c). The speciﬁcity of the MZF1 antibody
was veriﬁed by IHC staining of parafﬁn sections of MCF7
breast cancer cells expressing doxycycline-inducible
MZF1 (Supplementary Figure S1b) and with a peptide
competition assay (Supplementary Figure S1c). MZF1
expression was increased in a panel of breast cancer cells
lines including MCF7, BT474, SK-BR-3, MDA-MB-231,
MDA-MB-436, and MDA-MB-468 when comparing with
non-cancerous, immortalized MCF10A cells (Supple-
mentary Figure S1d). Taken together these results show
that MZF1 is expressed in differentiated mammary epi-
thelia and that its expression is increased in primary
human breast cancer.
MZF1 renders breast cancer cells invasive in vitro
To investigate whether MZF1 could have a direct role in
the breast cancer invasiveness, we stably expressed a
doxycycline-inducible MZF1 expression construct in
poorly invasive MCF7 breast cancer cells that exhibit low
expression of all endogenous, ligand-induced ErbB
receptors24. We studied the invasiveness of doxycycline-
inducible MCF7-MZF1 1–6 clone in a 3D Matrigel inva-
sion assay (Fig. 1d; Supplementary Figure S1e). The
doxycycline-induced 3-fold increase in MZF1 protein
expression (Fig. 1e) was associated with increased inva-
siveness of MCF7-MZF1 1–6 cells (Fig. 1d). 1.5-fold
increase in the expression of MZF1 obtained with another
cell line expressing doxycycline-inducible MZF1 (MCF7-
MZF1 1–9) treated with 5 nM epidermal growth factor
(EGF) to induce ErbB signaling, resulted in modest
increase in the invasion of the MCF7 spheres (Supple-
mentary Figure S1e). Notably, doxycycline and EGF had
no effect on the invasiveness of the MCF7-vector cells
(Fig. 1d; Supplementary Figure S1e). Thus, the increased
expression of MZF1 can promote invasion of poorly
invasive MCF7 cells. Conversely, we have previously
shown that invasion of breast cancer cells expressing high
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levels of ErbB2 could be inhibited by reducing MZF1
expression with MZF1 siRNA13.
Let-7 miRNAs regulate MZF1 expression directly via the 3’-
UTR of MZF1
In search for mechanisms responsible for the upregu-
lation of MZF1 during breast cancer progression to IDC,
we screened the MZF1 3′-untranslated region (UTR) for
putative miRNA binding sites in microRNA.org (http://
www.microrna.org/microrna/home.do); a miRNA target
prediction resource based on the MiRanda algorithm25.
microRNA.org predicted a single putative binding site for
the let-7 family of miRNAs in the 3′-UTR of MZF1 with
probability of downregulation (mirSVR score: −0.1253 to
−0.1229) and miRNA conservation (PhastCons score:
0.3954) (Fig. 2a). Notably, no other miRNA target sites
were found in the 3′-UTR of MZF1 with these criteria.
The let-7 family members share a 7-nucleotide seed
region (5′-GAUGGAG-3′) with complete com-
plementarity to the MZF1 target sequence. In let-7e the
seed region is extended to 8-nucleotides (Fig. 2a). Using
mRNA expression array data (n= 547) and miRNA
sequencing data (n= 697) from The Cancer Genome
Atlas (TCGA; https://cancergenome.nih.gov/) database,
we correlated MZF1 mRNA expression with let-7 miRNA
expression employing a Spearman’s rank correlation
analysis. Supporting the miRNA.org prediction, we found
that the expression of 5, 6, and 7 out of 11 studied let-7
miRNA family members correlated negatively with the
expression of MZF1 in grade I, II and III+ IV, respec-
tively (Fig. 2b). One mechanisms proposed to be
responsible for the downregulation of let-7 in breast
cancer is the upregulation of the well-studied inhibitors of
let-7 processing; lin28A and lin28B26–28. Thus, we utilized
the mRNA expression array data from TCGA to investi-
gate the correlation between MZF1 and lin28A and lin28B
mRNA (LIN28A and LIN28B) in breast cancer and found
that MZF1 expression correlates positively with the
expression of lin28A, but not lin28B (Fig. 2c, d). This
suggests that lin28A could be involved in the regulation of
MZF1 expression via let-7 in breast cancer. Supporting
this, quantitative IHC of the breast cancer TMAs used in
Fig. 1a–c revealed a signiﬁcant positive correlation
between lin28A and MZF1 protein expression (Fig. 2e).
To study the effects of let-7 overexpression and inhi-
bition of MZF1 expression in breast cancer cells, we used
MCF7 cells that express both MZF1 (Supplementary
Figure S1d)13 and most of the let-7 family members29.
Consistent with the expression pattern of MZF1 in the
TMA described above (Fig. 1b) and in breast cancer cell
lines (supplementary Figure S1d), we found MZF1
expression to be higher in MCF7 breast cancer cells than
in the non-cancerous, immortalized MCF-10A breast
epithelial cells (Fig. 3a). By quantifying the expression of
ﬁve representatives of let-7 family members let-7d, let-7e,
let-7f, let-7g, and let-7i in these cell lines, we found that
the expression of let-7e and let-7g was signiﬁcantly lower
in MCF7 than in MCF10A cells (Fig. 3b).
We chose to continue cellular studies with three
representatives of let-7 family: let-7d, let-7e, and let-7g.
This choice was based on the results above and on earlier
publications that found let-7d and let-7g to be involved in
breast cancer cell invasion30,31. Additionally, let-7e was
chosen due its extended MZF1-complimentary seed
region (Fig. 2a). Extended seed regions have been shown
to enhance the efﬁciency of target down-regulation32.
Since the putative let-7 target site in the MZF1 3′UTR has
complete complementarity in the seed region and addi-
tional partial complementarity in the 3′-end to all mem-
bers of let-7 family (Fig. 2a), we assumed that the site is
likely regulated by all or none of the members of the let-7
family33.
In order to investigate whether let-7 overexpression
could reduce MZF1 expression in MCF7 cells, we
(see ﬁgure on previous page)
Fig. 1 MZF1 expression is increased in primary breast cancer samples and its expression induces cancer cell invasion in poorly invasive
breast cancer cells. a Examples of IHC staining of MZF1 (brown) in normal breast (upper panel), grade 1 breast cancer tissue (DCIS; middle panel),
grade 1–2 breast cancer tissue (lower panel). Sections were counterstained with hematoxylin (blue) and images were taken with 20× magniﬁcation. b
Association of MZF1 protein expression with tumor grade in primary breast cancer samples in TMAs including 321 primary samples of normal and
breast cancer tissue. TMAs were analyzed by ACIS-assisted quantitative IHC and ACIS scores of duplicate cores were averaged and plotted against the
breast cancer grade. The statistical difference in MZF1 expression between Normal and Grade 1–2 (IDC) is indicated by a * implicating a p-value < 0.05
according to a Mann–Whitney test. Mean values +/− SD is marked in red. c MZF1 expression in normal, benign and primary breast tumors of grade
1–3 from the same TMAs as in (b). d Invasion of MCF7 cells stably transfected with a doxycycline-inducible expression vector containing MZF1
(MCF7-MZF1 1–6) or an empty vector (MCF7-vector) in 3D Matrigel in the absence (−Dox) or presence of doxycyline (+Dox). Images were taken with
10x magniﬁcation. Quantiﬁcation of the average extend of outgrowth in (d) was done using ImageJ. For each of 4 spheres per treatment, the 10
greatest distances traveled by invading cells were estimated and a mean outgrowth was calculated for each treatment. Data presented is an average
of 2 independent experiments and as % of non-induced control (−Dox) and the comparison of −Dox and +Dox in MCF7-MZF1 1–6 cells is assigned
with **** indicating p < 0.0001 in a Welch’s t-test. e Immunoblot analysis of MZF1 expression in MCF7-vector and MCF7-MZF1 1-6 (+Dox) and without
(−Dox) doxycycline. β-actin was used as a control of equal loading. The immunoblot from a single control experiment was quantiﬁed using ImageJ,
normalized to β-actin and presented as % of MCF7-vector −Dox
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transfected MCF7 cells with 20 nM of let-7d, let-7e, and
let-7g miRNA mimics. Ectopic expression of let-7e and
let-7g signiﬁcantly decreased MZF1 mRNA expression
when comparing with a non-targeting control mimic (Fig.
3c). The effect of let-7d on MZF1 mRNA expression was
not signiﬁcant (Fig. 3c). To investigate the effect of let-7
inhibition on MZF1 expression, we used locked nucleic
acid (LNA) miRNA inhibitors. We transfected MCF7 cells
with 20 nM of LNA1 targeting let-7a, let-7b, let-7c, let-7d,
and let-7e, LNA2 targeting only mir-98 and LNA3 tar-
geting let-7f, let-7g and let-7i. LNA1 and LNA3, but not
LNA2, increased MZF1 mRNA expression signiﬁcantly
when comparing with a non-targeting control LNA (Fig.
3d). Supportively, transfection of MCF7 cells with a pool
of the let-7d, let-7e, and let7-e mimics and a pool of LNA1
and LNA3 decreased and increased the MZF1 protein
expression, respectively (Fig. 3e). Additionally, transfec-
tion of let-7 mimics d, e and g into breast cancer cell lines
SK-BR-3, MDA-MB-436, and MDA-MB-231 resulted in a
reduction in MZF1 protein expression in most of the
samples (Fig. 3f), suggesting a more general role of the
regulatory relationship between these let-7 family mem-
bers and MZF1 in breast cancer cells.
To investigate whether the effect of let-7 on MZF1
expression is a result of direct interaction between let-7
miRNAs and the MZF1 3′-UTR, we subcloned the MZF1
3′-UTR containing the let-7 target site (psiCHECK-2-
MZF1) and its mutated version (Mutated psiCHECK-2-
MZF1; CTACCTC to CAAGCAC) into a psiCHECK-2
luciferase expression vector. Luciferase assays showed
that expression of mimics of let-7d, let-7e, and let-7g
signiﬁcantly decreased the luciferase activity of the psi-
CHECK-2-MZF1, but not the mutated psiCHECK-2-
MZF1 in MCF7 cells (Fig. 3g). As a positive control, we
used a psiCHECK-2 expression vector containing two
synthetic let-7 binding sites (Pos. ctrl. psiCHECK-
2–2xlet7) (Fig. 3g).
Taken together these results show that let-7d, let-7e,
and let-7g can regulate MZF1 expression in various breast
cancer cells directly via a functional let-7 target site in the
MZF1 3′-UTR.
Let-7 regulates invasion and lysosomal distribution of
ErbB2-expressing breast cancer cells via MZF1
In order to study the effect of let-7 miRNAs on breast
cancer cell invasion, we used MCF7 cells rendered highly
invasive by inducible expression of constitutively active
95kDa N-terminally truncated form of ErbB2 (MCF7-
p95ΔNErbB2)13,34. Forced expression of let-7d, let-7e,
and let-7g decreased the invasive growth of MCF7-
p95ΔNErbB2 cells in 3D Matrigel (Fig. 4a). Let-7e was the
most efﬁcient of the tested let-7 family members, inhi-
biting invasion to the same extend as MZF1-targeting
siRNA (MZF1kd), when comparing with a non-targeting
control (Fig. 4a). The ectopic expression of let-7 mimics
had no signiﬁcant effect on survival of the MCF7-
p95ΔNErbB2 cells within the timeframe relevant for this
assay (Supplementary Figure S2a).
In order to investigate whether the effect of let-7 on
invasion is mediated by MZF1, we performed a rescue
experiment using co-expression of let-7e mimic and a
plasmid expressing wild type (WT) MZF1 lacking the 3′-
UTR. We chose to rescue the effect of let-7e since this was
the let-7 mimic with the most prominent effect on inva-
sion in these cells. Indeed, transient overexpression of this
WT MZF1 could rescue the inhibitory effect of let-7e on
invasion, suggesting that the effect is mediated by MZF1
(Fig. 4b, c). Transfection of MCF7-p95ΔNErbB2 cells with
the let-7e mimic did not signiﬁcantly affect the expression
of p95ErbB2 (Fig. 4d).
In MCF7-p95ΔNErbB2 cells, ErbB2 signaling induces a
malignant cellular morphology characterized by the
appearance of long cellular protrusions and a dramatic
redistribution of lysosomes to the cell periphery13,34. We
have previously shown that lapatinib, an EGFR/ErbB2
kinase inhibitor, inhibits invasion and alters the lysosomal
distribution from predominantly peripheral to pre-
dominantly perinuclear in ErbB2-positive ovarian cancer
cells14. Confocal immunoﬂuorescent microscopy of the
lysosomal distribution (LAMP2 staining) in MCF7-
p95ΔNErbB2 cells revealed a similar lapatinib-induced
retrograde trafﬁcking of lysosomes (Fig. 5a). The lapatinib
concentration used in this assay did not affect the survival
of the cells (Supplementary Figure S2b). Supporting the
(see ﬁgure on previous page)
Fig. 2 The MZF1 3′-UTR contains a putative let-7 target site and MZF1 expression correlates negatively with several let-7 family members
and positively with LIN28A in primary breast cancer samples. a Alignment of 9 let-7 family members to their putative target site in the MZF1 3′-
UTR (red). All let-7 family members are predicted to bind to the target site via a 7mer seed region (green), with the exception of let-7e binding with
an 8mer seed region. b Correlation plots for the correlation between let-7 and MZF1 RNA expression in primary breast cancer samples included in
TCGA data. Pairs that show positive correlation are depicted with red circles. Pairs that show negative correlation are depicted with blue circles. The
Spearman correlation coefﬁcient is depicted using the radius of the circle: the larger the coefﬁcient, the larger the radius. c Correlation plots of MZF1
and LIN28A expression in TCGA data (all stages). Highest 6% expressing LIN28A samples have been omitted from the ﬁgure to better show the
correlation. The correlation is assigned with *** indicating p < 0.001. d Correlation plots of MZF1 and LIN28B expression in TCGA (all stages). e
Association between MZF1 and Lin28A protein expression quantiﬁed from the same TMAs as described in Fig. 1a–c. The Spearman correlation is
signiﬁcant with p < 0.0001
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role for MZF1 in ErbB2-induced anterograde trafﬁcking
of lysosomes, its depletion by let-7e and let-7d mimics or
MZF1 siRNA reduced the proportion of peripheral lyso-
somes while increasing that of perinuclear lysosomes (Fig.
5b). Forcing the expression of let-7g had no effect on the
predominant lysosomal localization (Fig. 5b). Since the
effect on lysosome distribution in these cells was most
prominent when overexpressing the let-7e mimic, we
performed a rescue experiment using let-7e and ectopi-
cally expressed MZF1. Similar to the effect on invasion,
Fig. 3 (See legend on next page.)
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the effect of let-7e on the lysosomal distribution could be
rescued by the transient overexpression of MZF1 lacking
the 3′-UTR (Fig. 5b).
These results indicate that ectopic expression of let-7
family members can effectively counteract MZF1-
mediated invasion and related peripheral distribution of
lysosomes.
Discussion
MZF1 is a zinc-ﬁnger transcription factor expressed in
myeloid progenitor cells where its function is to regulate
hematopoietic differentiation35. MZF1 is also expressed in
various epithelial cancers, including breast cancer, where
it promotes tumor progression13,36–45. The knowledge of
its role in breast cancer has been limited to the fact that it
is ErbB2-responsive and that it contributes to invasion by
upregulating CTSB and PRKCA (protein kinase C alpha)
expression in various breast cancer cell lines13,39,45. In this
study, we show that MZF1 expression is increased during
breast cancer progression from normal epithelium to
DCIS and IDC and that increased MZF1 expression can
induce invasion of poorly invasive, MCF7 breast cancer
cells in 3D Matrigel cultures. Thus, MZF1 may contribute
to the progression of mammary ductal epithelial cells to
abnormal cells conﬁned in the duct, and ﬁnally to invasive
breast cancer. By identifying MZF1 as a novel target of let-
7, this study further suggests that the lack of let-7 sup-
pression on MZF1, could result in MZF1 upregulation
and thus contribute to oncogenesis and breast cancer
progression.
Despite extensive evidence that loss of let-7 expression
associates with invasive and metastatic disease and poor
patient outcome in breast cancer30,31,46,47, the factor/s
linking these two are still not understood. In this study,
we present a functional link between let-7 family mem-
bers and breast cancer cell invasion, by identifying MZF1
as a novel target of let-7 and by connecting let-7 to the
invasion-promoting lysosomal distribution of ErbB2-
positive breast cancer cells via MZF1. Previous studies
have identiﬁed additional oncogenic let-7 targets. Among
these are the High Mobility Group 1 and 2 A (HMGA1
and 2 A) protein, BACH1, estrogen receptor α (ERα), the
proto-oncogenes c-Myc and Ras46,48–52. The contribution
of these let-7 targets to the invasion of ErbB2-positive
breast cancer cells has not been addressed. However, the
fact that the ectopic expression of MZF1 lacking the 3′
UTR can fully rescue the let-7-mediated inhibition of
invasion of ErbB2-positive cells in this study, suggests that
the invasion-inhibiting function of let-7 in these cells
could be mediated by MZF1. Moreover, our ﬁnding that
in breast cancer cells the level of MZF1 and consequently,
the MZF1-controlled anterograde lysosome trafﬁcking
can be regulated by let-7, identiﬁes a previously unnoticed
function for this well-studied miRNA family.
Here we conclude that MZF1 expression is needed for
the ErbB2-induced, invasion-promoting anterograde
lysosomal trafﬁcking in breast cancer cells. This adds to
its previously reported role as a transcriptional regulator
of cathepsins B and L upon ErbB2 activation13. Thus,
MZF1 performs similar functions in breast cancer cells as
TFEB, also known as a master regulator of the Coordi-
nated Lysosomal Expression and Regulation (CLEAR)
network, has in normal cells. TFEB function is negatively
regulated by mTOR and ERK. Phosphorylation of TFEB
(see ﬁgure on previous page)
Fig. 3 Let-7 miRNAs regulate MZF1 expression by directly binding to its 3′-UTR. a Representative IHC staining of MZF1 in sections made from
formalin-ﬁxed, parafﬁn-embedded (FFPE) MCF10A and MCF7 cell pellets. Sections were counterstained with hematoxylin (blue) and images were
taken with 40x magniﬁcation. MZF1 expression in MCF10A and MCF7 cells was quantiﬁed using ACIS-assisted analysis. b Let-7 expression in MCF10A
and MCF7 cells. Expression of let-7d, let-7e, let-7f, let-7g, and let-7i was quantiﬁed using TaqMan miRNA assay and qPCR. The relative miRNA quantity
was calculated by 2-ΔCt using U6 RNA as an internal reference. U6 RNA was expressed at similar levels in MCF10A and MCF7 cells. Data are presented
as the means of two independent experiments with three technical replicates ± SD. The comparison of MCF10A and MCF7 cells according to let-7e-
and let-7g-expression is assigned with ** indicating p < 0.01 and **** indicating p < 0.0001 in Welch’s t-test. c The effect of let-7d, let-7e and let-7 g
mimics (20 nM) on MZF1 mRNA level relative to non-targeting control mimic in MCF7 cells. MZF1 mRNA expression was quantiﬁed by RT-qPCR with
PPIB as reference gene. Data are presented as the mean of six (let-7d and let-7e) and ﬁve (let-7g) independent experiments ± SD and signiﬁcance is
indicated with * for p < 0.05 in a Welch’s t-test. d The effect of miRNA inhibitors LNA1, LNA2 and LNA3 (20 nM) targeting different let-7 family
members on MZF1 mRNA expression relative to an LNA negative control in MCF7 cells. Data are presented as the mean of three independent
experiments ± SD and signiﬁcance is indicated with * and ** for p < 0.05 and p < 0.01 in a Welch’s t-test, respectively. e Immunoblot-analysis of MZF1
protein expression in response to a let-7 pool (let-7d, let-7e, and let-7g, 20 nM) or LNA pool (LNA1 and LNA3, 20 nM). β-actin was used to control the
equal loading. The immunoblot is a representative of three independent blots that were quantiﬁed using ImageJ. Data are presented as the mean of
three experiments ± SD relative to control. Signiﬁcance is indicated with * for p < 0.05 in a Welch’s t-test. f Immunoblot-analysis of MZF1 protein
expression in response to a transfection with 20 nM of let-7d, let-7e, and let-7 g mimic and a non-targeting control in SKBR3, MDA-MB-231 and MDA-
MB-436 cells. β-actin was used to control the equal loading. The immunoblot is a representative of three independent blots. g Luciferase reporter
assay measuring the hluc + − and hRluc-response of psiCHECK-2-MZF1, Mutated psiCHECK-2-MZF1 and a positive control psiCHECK-2–2xlet-7 to
mimics of let-7d, let-7e and let-7g (20 nM). Data are presented as the mean of 12 independent experiments for psiCHECK-2-MZF1 and mutated
psiCHECK-2-MZF1 and 4 independent experiments for psiCHECK-2–2xlet7. Data are presented as the mean of experiments ± SD relative to control
mimic and signiﬁcance is indicated with *, **, ***, and **** for p < 0.05, 0.01, 0.001, and 0.0001 in a Welch’s t-test, respectively
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by mTOR and ERK kinases masks the nuclear localization
signal of TFEB and sequesters it in the cytosol, where it
cannot activate the expression of its target genes17,53,54.
Thus, TFEB is most likely not involved in the regulation of
the ErbB2-induced, invasion-promoting lysosomal
alterations in breast cancer cells, since ErbB2 activation
leads to the activation of the mTOR and MAPK-ERK
signaling pathways55. Supportively, TFEB was found not
to be involved in the ErbB2-induced expression of CTSB,
a central lysosomal hydrolase belonging to the CLEAR
network13. This data altogether suggests that MZF1 can,
at least partially, take over some of the functions of TFEB
in breast cancer cells.
One potentially important implication of this study is
the identiﬁcation of MZF1 as the factor that can uncouple
the oncogene-induced lysosomal alterations from the
TFEB-regulated CLEAR network, which is highly impor-
tant for the normal cellular wellbeing. The fact that these
two processes can be regulated by different factors in
cancer cells versus normal cells makes MZF1 and the
lysosomal alterations it induces attractive targets for anti-
cancer drug development. Thus, discovering and under-
standing how the lysosomal compartment in cancer cells
differs from that of normal cells and what regulates these
differences, will allow the intervention of invasion-
promoting processes of cancer cells without interfering
with the cellular clearance and wellbeing of normal cells.
Materials and methods
Tissue Culture and cell lines
Human breast cancer cell lines MCF756 were grown in
RPMI1640 GlutamaxTM; SK-BR-3, MDA-MB-231, MDA-
MB-436 and MDA-MB-468 (ATCC, Manassas, VA, USA)
in DMEM GlutaMAXTM; BT474 (ATCC) in DMEM/F-12
(GIBCOTM, Invitrogen, Carlsbad, CA, USA) supple-
mented with 6 or 10% of heat inactivated fetal bovine
serum (FBS) (GIBCOTM, Invitrogen). The human breast
epithelial cell line MCF10A (ATCC) was cultured in
DMEM/F-12 (GIBCOTM, Invitrogen) supplemented with
5% horse serum (GIBCOTM, Invitrogen), 10 µg EGF
(Sigma-Aldrich E-H127, St. Louis, MO, USA), 250 µg
hydrocortisone (VWR CALB3867-1, Radnor, PA, USA),
50 µg CholeraToxin (Sigma-Aldrich C-8052), and 5mg
insulin (Sigma-Aldrich I-9278). All the cells were grown
in the presence of 100,000 units/mL penicillin and 12.5
µg/mL streptomycin (Invitrogen). Doxocycline inducible
MZF1 expressing cells were prepared by amplifying the
coding sequence of full-length MZF1 by PCR using a
QIAGEN LongRange PCR kit (QIAGEN, Hilden, Ger-
many) and cloning the DNA fragment into the EcoRI site
of the pVLX-Tight-Puro-Tet-On Advanced vector. Con-
struct was conﬁrmed by sequencing. The inducible MZF1
expression vector was stably transfected into MCF7 and
the culture media was supplemented with 200 µg/mL
G418 and 1 µg/mL puromycin to obtain single cell MZF1
expressing clones 1–6 and 1–9. MCF7 p95ΔN-ErbB2 cells
were cultured and the expression of ErbB2 was induced as
described previously13,34. All cell lines were kept at 37 °C
in a humidiﬁed atmosphere of 5% CO2.
Immunohistochemical (IHC) staining of formalin-ﬁxed
parafﬁn-embedded (FFPE) cell lines and tissues
Tissue microarrays (TMAs) were purchased from Pan-
tomics (BRC961, BRC962 BRC1501, BRC1502, BRC1503),
Richmond, CA, USA). Additional tissue samples of nor-
mal breast tissue were produced and processed as pre-
viously published57. FFPE cell-blocks were prepared as in
Cabezon et al.58. Five micrometer sections were stained
with primary antibody against MZF1 (Abcam ab64866,
1:1000, Cambridge, UK) or Lin28A (Abcam ab46020,
1:1000). The sections were scanned and assessed in an
ACIS® III Instrument (DAKO). IHC quantiﬁcation was
done by ACIS III-assisted analysis. The stained sections
were scanned and brown intensity was quantiﬁed with
manually placed 40× regions (3 per section/core) and a
color threshold customized for MZF1.
(see ﬁgure on previous page)
Fig. 4 Let-7 miRNAs inhibit invasion of invasive breast cancer cells by reducing MZF1 expression. a Invasion of MCF7-p95ΔNErbB2 cells in 3D
Matrigel upon transfection with 20 nM control, let-7d, let-7e, and let-7g mimic and MZF1 siRNA. Images of the invasive spheres were taken at 10×
magniﬁcation. Quantiﬁcation of the average extend of outgrowth in (a) was done using ImageJ. For each of 5 spheres per treatment, the 10 greatest
distances traveled by invading cells were estimated and a mean outgrowth was calculated for each treatment. Data are presented as % of control
mimic and the effect of let-7e and MZF1kd is assigned with *, **, and *** indicating p < 0.05, p < 0.01, and p < 0.001, respectively, in a Welch’s t-test. b
Invasion of MCF7-p95ΔNErbB2 cells in 3D Matrigel upon transfection with a control and 20 nM let-7e mimic in the absence and presence of
transiently expressed WT MZF1 lacking the 3′-UTR. Images of the invasive spheres were taken with 10× magniﬁcation. Quantiﬁcation is done as
described in a. Data are presented as % of control and the effect of let-7e is assigned with * indicating p < 0.05 in a Welch’s t-test. c Immunoblot
analysis of MZF1 protein expression in MCF7-p95ΔNErbB2 cells transfected with 20 nM of control and let-7e mimic in the absence and presence of
transient overexpression of WT MZF1. β-actin was used to control for equal loading. The immunoblot was quantiﬁed using Image Studio Lite. Data
are presented as relative to control mimic treatment in the absence of transient WT MZF1 overexpression. d Immunoblot analysis of ErbB2 protein
expression in MCF7-p95ΔNErbB2 cells response to forced let-7e expression (20 nM). β-actin was used to control the equal loading. The immunoblot is
a representative of three independent experiments that were quantiﬁed using Image Studio Lite. Data are presented as the mean of experiments ±
SD relative to control. The effect was non-signiﬁcant according to a Welch’s t-test
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Transfections
To force and inhibit the expression of let-7 miRNAs we
used hsa-let-7d, has-let-7e and Negative Control 2 (Mis-
sion® microRNA, Sigma-Aldrich) and locked nucleic acids
(LNAs) hsa-let7 F1 (LNA1) targeting hsa-let-7a, hsa-let-
7b, hsa-let-7c, hsa-let-7d and hsa-let-7e, hsa-let-7 F2
(LNA2) targeting hsa-mir98, hsa-let-7 F3 (LNA3) target-
ing hsa-let-7f, hsa-let-7g and hsa-let-7i and, negative
control B (miRCURY® LNAs, Exiqon, Vedbaek, Denmark),
respectively, in a ﬁnal concentration of 20 nM. As a
control, siRNA targeting MZF1 (# sc-45714A; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) was also included.
Reverse transfection with mimics, LNAs and siRNA (20
nM) were performed in 6-well or 96-well culturing plates
with RNAiMAX (InvitrogenTM) according to manu-
facturer’s protocol. Cells were harvested after 24, 48, and
72 h for invasion, RNA and protein, respectively. Trans-
fections with a pcDNA3.1 vector containing the WT
MZF1 were performed in 6-well culturing plates using
Fugene HD (Promega, Madison, WI, USA) as a trans-
fection reagent according to manufacturer’s protocol.
RNA isolation and quantiﬁcation
Total RNA was isolated and puriﬁed using TRIzol
Reagent (Invitrogen) followed by phenol-chloroform
extraction (Sigma-Aldrich) and precipitation. Let-7 miR-
NAs were quantiﬁed from RNA samples using a TaqMan®
MicroRNA Assay (Life Technologies Carlsbad, CA, USA)
according to manufacturer’s protocol. For quantitative
PCR to determine the mRNA levels of MZF1, RNA was
isolated using NucleospinTM Total RNA Isolation Kit
(Macherey-Nagel, Düren, Germany) according to the
manufacturers protocol. The cDNA was synthesized from
1 µg RNA with Oligo(dT) primers using a TaqManTM
Reverse Transcription Kit (Roche Diagnostics, Basel,
Switzerland). QPCR analysis was performed using SYBR
Green QPCR reagents (Agilent Technologies, Santa Clara,
CA, USA) in a 7500 Fast Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA). The expression of
target genes was normalized to the expression of the
housekeeping gene Cyclophilin B (PPIB). The Pfafﬂ
method, which takes primer efﬁciencies into account, was
used to calculate Relative mRNA levels were calculated
using the Pfafﬂ method59. Following primers were used
for quantitative PCR:
MZF1 forward: 5′- TGG GCC TCT AGC TGC CAC
CC-3′ (efﬁciency 1.866076)
MZF1 reverse: 5′- GGT CCC ACA TCT CTG GGC
CTC C-3′ (efﬁciency 1.866076)
PPIB forward: 5′- GGG AGA TGG CAG AGG AGG
AAA −3′ (efﬁciency 1.739843)
PPIB reverse: 5′-TGG GAG CCG TTG GTG TCT
TTG-3′ (efﬁciency 1.739843)
Immunoblotting
Immunoblotting was performed as described
before13,14. The primary antibodies used were anti-MZF1
(Abcam, ab64866), anti-ErbB2 (Thermo Scientiﬁc, ab-17,
Waltham, MA, USA) and anti-β-actin (Sigma-Aldrich,
A2228). Images were quantiﬁed using Image J or Image
Studio Lite.
Luciferase assay with psiCHECKTM-2 reporter
The MZF1 3′UTR region from a pMirTarget Reporter
(OriGene® Technologies, Rockville, MD, USA) was
transferred to a psiCHECK-2 vector (Promega) by diges-
tion with NotI and SgfI followed by ligation using the
Rapid DNA Ligation kit (Roche Diagnostics) according to
the manufacturers protocol. Correct insertion of the
MZF1 3′UTR into the psiCHECK-2 vector was conﬁrmed
by sequencing. Let-7 mimics were reverse transfected into
MCF7 cells as previously described, following forward
transfection with psiCHECK-2-MZF1 after 24 h using
Fugene HD (Promega) according to manufacturer’s pro-
tocol. Luciferase assays were performed using Dual-
luciferaseTM Reporter Assay System (Promega) and
measured with a Varioskan® Flash Spectral Scanning
Reader (Thermo Scientiﬁc). Renilla luciferase activities
were normalized to ﬁreﬂy luciferase activities.
To mutate the let-7 target site in the psiCHECK-2-
MZF1, three substitutions were introduced in the seed
region (CTACCTC->CAAGCAC) by site-directed
(see ﬁgure on previous page)
Fig. 5 Let-7 miRNAs reverse ErbB2-induced peripheral distribution of lysosomes by reducing MZF1 expression. a Confocal
immunoﬂuorescence microscopy images of the lysosomal distribution in MCF7-p95ΔNErbB2 cells treated with DMSO or 5 μM lapatinib for 24 h. After
treatment, cells were ﬁxed and stained for the lysosomal membrane protein LAMP2 (green), cytoskeletal α-tubulin (red) and nucleus with Hoechst
(blue). Quantiﬁcation of (a) was done by characterizing the lysosomal distribution as predominantly perinuclear, scattered or peripheral in 8–15 cells
per 63× image in ﬁve images per treatment. Data represents the mean percentage distribution of ﬁve images ± SD. The effect of lapatinib on the
peripheral pool of lysosomes is assigned with *** indicating p < 0.001 in a Welch’s t-test. b Confocal immunoﬂuorescence microscopy images of the
lysosomal distribution in MCF7-p95ΔNErbB2 cells transfected with 20 nM of a non-targeting control, let-7d, let-7e, and let-7g mimic and MZF1 siRNA
(MZF1kd) and the non-targeting control and let-7e mimic in the presence of transiently expressed WT MZF1 lacking the 3′-UTR. Quantiﬁcation of (b)
was done as described in for (a). The effect of let-7 mimics and MZF1 siRNA on the peripheral pool of lysosomes is assigned with *, **, and ***
indicating p < 0.05, p < 0.01, and p < 0.001 in a Welch’s t-test. The data presented in A and B are representative of three independent experiments
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mutagenesis. Mutagenesis primers were designed using
the QuikChange® Primer Design program from Agilent
Technologies (https://www.genomics.agilent.com/
primerDesignProgram.jsp) (Mut forward: 5′- GCC ATG
GTC AGA ACA CCA AGC ACC CCT GGT TAT TGT
GAG-3′ and Mut reverse: 5′- CTC ACA ATA ACC AGG
GGT GCT TGG TGT TCT GAC CAT GGC-3′). The
mutations were introduced using PfuUltra II Fusion HS
DNA polymerase (Agilent Technologies) and the Dpn I
restriction enzyme (10 U/µL) at 37 °C for 1–2 h, to remove
the parental supercoiled dsDNA vector. The resulting
mutated psiCHECK2-MZF1 was veriﬁed by sequencing. A
psiCHECK-2 vector containing a tandem let-7 target site
(psiCHECK-2–2xlet-7) was included as a positive control
(Addgene plasmid #20929, Cambridge, MA, USA).
3D Invasion assay
A day after transfection, 3D cell spheres were made with
a hanging drop method13 or with a spinning method60 in
RPMI supplemented with 6% heat inactivated FCS. 20–24
h later spheres were embedding into Matrigel (Growth
factor reduced, BD Biosciences no. 354263, San Jose, CA,
USA) containing 1.5% FCS and incubated in surrounding
RPMI supplemented with 10% of fresh FCS for maximal
utilization of serum-based growth factors as chemo
attractants. 5 nM EGF was used as additional stimulus,
when needed. Spheres were followed carefully up to four
days during which the extent of the outgrowth from the
spheres was carefully followed. Images were taken with
Olympus 1× 71 light microscope supplemented with Cell
P software. For each of 5–6 spheres per treatment, the 10
greatest distances traveled by invading cells were esti-
mated in ImageJ and a mean outgrowth was calculated for
each treatment.
Immunoﬂuorescence microscopy
For lapatinib-treatment, cells were seeded on glass
coverslips in 6-well culturing plates (NUNC, Thermo
Scientiﬁc) 24 h prior to treatment. For mimic, LNA and
siRNA transfections, cells were transfected and seeded
onto coverslips simultaneously. For ﬁxation, cells were
washed twice with PBS, incubated for 20min. with 3.7%
formaldehyde at room temperature, incubated with
methanol for 3 min. at −20 °C, and ﬁnally washed twice
with PBS.
Immunoﬂuorescent staining was performed as descri-
bed before14. Primary antibodies used were LAMP2
(Abcam ab25631, 1:400) and α-tubulin (Abcam ab15246,
1:600). Images were taken with a LSM700 laser scanning
confocal microscope (Carl Zeiss, Inc, Dublin, CA, USA) at
63× magniﬁcation. Quantiﬁcation of the lysosomal dis-
tribution was done as described before14. For quantiﬁca-
tion, 5 images per treatment were analyzed in each
independent experiment and classiﬁed the lysosomal
distribution in 8–15 cells per image.
Cell survival assays
Cells were plated in a 96-well plate (5000 cells/well) or a
6-well plate (300,000 cells/well) and allowed to attach for
18 h before indicated treatment (Lapatinib dose-response)
or reverse transfection (Let-7 mimic), respectively. After
24 h (Lapatinib dose-response) or 72 h (Let-7 mimic
transfection), the plates were stained with 0.333 µg/ml
propidium iodide (Sigma-Aldrich, P4864) and 0.1 µg/ml
Hoechst 33342 (Life Technologies, H1399) for 10 min at
37 °C to label dead and total cells, respectively. Samples
were analyzed with the Celigo Cell Imaging Cytometer
(Brooks) to image the entire well surface and quantiﬁed
with the Celigo software.
Computational analysis
Computational analysis was carried out with the
Anduril framework (PMID: 20822536). RNA and micro-
RNA sequencing data was downloaded from the Cancer
Genome Atlas (TCGA) for 752 unique breast tumors for
which both measurement types were available (PMID:
23000897). Both data were level 3 and had been pre-
processed by TCGA as described in (PMID: 23000897). In
addition, the tumor stage information was downloaded
for each sample. For RNAseq data, the number of reads
per kilobase per million (RPKM) was extracted and these
counts were transformed to log2 scale. Before the loga-
rithmic conversion, 1 was added to each count to avoid
numerical errors. For miRNA data the number of reads
per million miRNA mapped was used and similary to
RNAseq they were converted to base two logarithmic
scale. Correlation was calculated with the Spearman
method.
Accession numbers
The TSP study accession number in the database of
Genotype and Phenotype (dbGaP) for the TCGA study
used here is phs000569.v1.p7 (breast cancer).
Statistics
Data are presented as mean± SD of the number of
experiments stated in ﬁgure legends. Data were analyzed
by unpaired two-tailed Student’s t-test with Welch cor-
rection or as described in the ﬁgure legends. Statistical
analysis was done using GraphPad Prism version 6.0e for
Mac OS X (GraphPad Software). In all cases, P< 0.05 was
considered statistically signiﬁcant. The statistical sig-
niﬁcance is illustrated with p-values; *p< 0.05; **p< 0.01;
***p< 0.001; and ****p< 0.0001. Samples were only
excluded from data if technical issues were evident.
Tvingsholm et al. Oncogenesis  (2018) 7:14 Page 13 of 15
Oncogenesis
Acknowledgements
We acknowledge Maria Grønvig Nielsen for excellent histology assistance and
Anders Lund for advice with the miRNA studies. This work is supported by the
Novo Nordisk Foundation (NNF12OC0002258), the Danish Medical Research
Council (0602-02386B), the Danish Cancer Society Scientiﬁc Committee (KBVU)
(R56-A3108-12-S2), the Lundbeckfonden (R67-A6310), the Danish National
Research Foundation (DNRF125), and the European Research Council (AdG
340751). The results published here are in part based upon data generated by
The Cancer Genome Atlas pilot project established by the NCI and NHGRI.
Information about TCGA and the investigators and institutions who constitute
the TCGA research network can be found at http://cancergenome.nih.gov/.
Author details
1Cell Death and Metabolism, Center for Autophagy, Recycling and Disease,
Danish Cancer Society Research Center, Strandboulevarden 49 2100
Copenhagen, Denmark. 2Biotech Research and Innovation Centre, University of
Copenhagen, Copenhagen, Denmark. 3Systems Biology Laboratory, Genome-
Scale Research Program, Faculty of Medicine, University of Helsinki, Helsinki,
Finland. 4Department of Drug Design and Pharmacology, Faculty of Health
and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
5Breast Cancer Biology, Genome Integrity Group, Center for Autophagy,
Recycling and Disease, Danish Cancer Society Research Center, Copenhagen,
Denmark
Authors contributions
S.A.T. contributed to Figs. 1a–d, 2a, e, 3a–e, 4a–d, 5a, b, and Supplementary
Figures 1 and 2, and manuscript editing; M.B.H. contributed for the Figs. 5a, 3d,
5b and Supplementary Figures 1d–e and 2b; K.K.B.C. contributed to the Figs.
1d–e, 2d, 3c, 4b, d, and manuscript editing; D.M.B. contributed to Figs. 1d, 3c,
4b, and 5a, b; B.R. contributed for preliminary experiments that this study was
based on; R.L. and S.H. contributed to Fig. 2b–d; L.B.F. contributed for the Fig.
3c; J.M. contributed to the Fig. 1c; I.G. contributed for the Fig. 1a–c; R.L. and S.H.
contributed to the Fig. 2b and c, M.J. contributed for manuscript editing and
planning; T.K. contributed for manuscript planning, writing, editing, and
planning of the project.
Conﬂict of interest
The authors declare that they have no conﬂict of interest.
Supplementary Information accompanies this paper at https://doi.org/
10.1038/s41389-017-0014-6.
Received: 7 June 2017 Accepted: 7 November 2017
References
1. Saftig, P. & Klumperman, J. Lysosome biogenesis and lysosomal membrane
proteins: trafﬁcking meets function. Nat. Rev. Mol. Cell. Biol. 10, 623–635 (2009).
2. Kallunki, T., Olsen, O. D. & Jaattela, M. Cancer-associated lysosomal changes:
friends or foes? Oncogene 32, 1995–2004 (2013).
3. Gocheva, V. & Joyce, J. A. Cysteine cathepsins and the cutting edge of cancer
invasion. Cell. Cycle 6, 60–64 (2007).
4. Arvatz, G., Shafat, I., Levy-Adam, F., Ilan, N. & Vlodavsky, I. The heparanase
system and tumor metastasis: is heparanase the seed and soil? Cancer
Metastas-. Rev. 30, 253–268 (2011).
5. Mason, S. D. & Joyce, J. A. Proteolytic networks in cancer. Trends Cell. Biol. 21,
228–237 (2011).
6. Olson, O. C. & Joyce, J. A. Cysteine cathepsin proteases: regulators of cancer
progression and therapeutic response. Nat. Rev. Cancer 15, 712–729 (2015).
7. Fehrenbacher, N. et al. Sensitization to the lysosomal cell death pathway upon
immortalization and transformation. Cancer Res. 64, 5301–5310 (2004).
8. Gocheva, V. et al. Distinct roles for cysteine cathepsin genes in multistage
tumorigenesis. Genes. Dev. 20, 543–556 (2006).
9. Fonovic, M. & Turk, B. Cysteine cathepsins and extracellular matrix degradation.
Biochim. Biophys. Acta 1840, 2560–2570 (2014).
10. Sobotic, B. et al. Proteomic identiﬁcation of cysteine cathepsin substrates shed
from the surface of cancer Cells. Mol. Cell. Proteom. 14, 2213–2228 (2015).
11. Vasiljeva, O. et al. Tumor cell-derived and macrophage-derived cathepsin B
promotes progression and lung metastasis of mammary cancer. Cancer Res.
66, 5242–5250 (2006).
12. Sevenich, L. et al. Transgenic expression of human cathepsin B promotes
progression and metastasis of polyoma-middle-T-induced breast cancer in
mice. Oncogene 30, 54–64 (2011).
13. Rafn, B. et al. ErbB2-driven breast cancer cell invasion depends on a complex
signaling network activating myeloid zinc ﬁnger-1-dependent cathepsin B
expression. Mol. Cell. 45, 764–776 (2012).
14. Brix, D. M. et al. Screening and identiﬁcation of small molecule inhibitors of
ErbB2-induced invasion. Mol. Oncol. 8, 1703–1718 (2014).
15. Rafn, B. & Kallunki, T. A way to invade: a story of ErbB2 and lysosomes. Cell.
Cycle 11, 2415–2416 (2012).
16. Hamalisto, S. & Jaattela, M. Lysosomes in cancer-living on the edge (of the
cell). Curr. Opin. Cell. Biol. 39, 69–76 (2016).
17. Settembre, C. et al. TFEB links autophagy to lysosomal biogenesis. Science 332,
1429–1433 (2011).
18. Medina, D. L. et al. Transcriptional activation of lysosomal exocytosis promotes
cellular clearance. Dev. Cell. 21, 421–430 (2011).
19. Nana-Sinkam, S. P. & Croce, C. M. MicroRNAs as therapeutic targets in cancer.
Transl. Res. 157, 216–225 (2011).
20. Boyerinas, B., Park, S. M., Hau, A., Murmann, A. E. & Peter, M. E. The role of let-7
in cell differentiation and cancer. Endocr. Relat. Cancer 17, F19–F36 (2010).
21. Yu, F. et al. let-7 regulates self renewal and tumorigenicity of breast cancer
cells. Cell 131, 1109–1123 (2007).
22. Dangi-Garimella, S. et al. Raf kinase inhibitory protein suppresses a metastasis
signalling cascade involving LIN28 and let-7. EMBO J. 28, 347–358 (2009).
23. Barh, D., Malhotra, R., Ravi, B. & Sindhurani, P. MicroRNA let-7: an emerging
next-generation cancer therapeutic. Curr. Oncol. 17, 70–80 (2010).
24. Nagashima, T. et al. Quantitative transcriptional control of ErbB receptor sig-
naling undergoes graded to biphasic response for cell differentiation. J. Biol.
Chem. 282, 4045–4056 (2007).
25. Betel, D., Wilson, M., Gabow, A., Marks, D. S. & Sander, C. The microRNA.org
resource: targets and expression. Nucleic Acids Res. 36(Database issue),
D149–D153 (2008).
26. Viswanathan, S. R., Daley, G. Q. & Gregory, R. I. Selective blockade of microRNA
processing by Lin28. Science 320, 97–100 (2008).
27. Piskounova, E. et al. Lin28A and Lin28B inhibit let-7 microRNA biogenesis by
distinct mechanisms. Cell 147, 1066–1079 (2011).
28. Sakurai, M. et al. LIN28: a regulator of tumor-suppressing activity of let-7
microRNA in human breast cancer. J. Steroid Biochem. Mol. Biol. 131, 101–106
(2012).
29. Fix, L. N., Shah, M., Efferth, T., Farwell, M. A. & Zhang, B. MicroRNA expression
proﬁle of MCF-7 human breast cancer cells and the effect of green tea
polyphenon-60. Cancer Genom. Proteom. 7, 261–277 (2010).
30. Iorio, M. V. et al. MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65, 7065–7070 (2005).
31. Qian, P. et al. Pivotal role of reduced let-7g expression in breast cancer
invasion and metastasis. Cancer Res. 71, 6463–6474 (2011).
32. Grimson, A. et al. MicroRNA targeting speciﬁcity in mammals: determinants
beyond seed pairing. Mol. Cell. 27, 91–105 (2007).
33. Brennecke, J., Stark, A., Russell, R. B. & Cohen, S. M. Principles of microRNA-
target recognition. PLoS. Biol. 3, e85 (2005).
34. Egeblad, M., Mortensen, O. H. & Jaattela, M. Truncated ErbB2 receptor
enhances ErbB1 signaling and induces reversible, ERK-independent loss of
epithelial morphology. Int. J. Cancer 94, 185–191 (2001).
35. Hromas, R. et al. A retinoic acid-responsive human zinc ﬁnger gene, MZF-1,
preferentially expressed in myeloid cells. J. Biol. Chem. 266, 14183–14187
(1991).
36. Mudduluru, G., Vajkoczy, P. & Allgayer, H. Myeloid zinc ﬁnger 1 induces
migration, invasion, and in vivo metastasis through Axl gene expression in
solid cancer. Mol. Cancer Res. 8, 159–169 (2010).
37. Hsieh, Y. H., Wu, T. T., Huang, C. Y., Hsieh, Y. S. & Liu, J. Y. Suppression of
tumorigenicity of human hepatocellular carcinoma cells by antisense oligo-
nucleotide MZF-1. Chin. J. Physiol. 50, 9–15 (2007).
38. Hsieh, Y. H. et al. PKCalpha expression regulated by Elk-1 and MZF-1 in human
HCC cells. Biochem. Biophys. Res. Commun. 339, 217–225 (2006).
39. Yue, C. H. et al. Expression of protein kinase C alpha and the MZF-1 and Elk-1
transcription factors in human breast cancer cells. Chin. J. Physiol. 55, 31–36
(2012).
Tvingsholm et al. Oncogenesis  (2018) 7:14 Page 14 of 15
Oncogenesis
40. Yue, C. H. et al. MZF-1/Elk-1 complex binds to protein kinase Calpha promoter
and is involved in hepatocellular carcinoma. PLoS. One 10, e0127420 (2015).
41. Tsai, L. H. et al. The MZF1/c-MYC axis mediates lung adenocarcinoma pro-
gression caused by wild-type lkb1 loss. Oncogene 34, 1641–1649 (2015).
42. Weber, C. E. et al. Osteopontin mediates an MZF1-TGF-beta1-dependent
transformation of mesenchymal stem cells into cancer-associated ﬁbroblasts
in breast cancer. Oncogene 34, 4821–4833 (2015).
43. Deng, Y. et al. p55PIK transcriptionally activated by MZF1 promotes colorectal
cancer cell proliferation. Biomed. Res. Int. 2013, 868131 (2013).
44. Hromas, R. et al. Aberrant expression of the myeloid zinc ﬁnger gene, MZF-1, is
oncogenic. Cancer Res. 55, 3610–3614 (1995).
45. Lee, C. J. et al. MZF-1/Elk-1 interaction domain as therapeutic target for protein
kinase Calpha-based triple-negative breast cancer cells. Oncotarget 7,
59845–59859 (2016).
46. Yun, J. et al. Signalling pathway for RKIP and Let-7 regulates and predicts
metastatic breast cancer. EMBO J. 30, 4500–4514 (2011).
47. Chen, L. et al. Role of deregulated microRNAs in breast cancer progression
using FFPE tissue. PLoS. One 8, e54213 (2013).
48. Johnson, S. M. et al. RAS is regulated by the let-7 microRNA family. Cell 120,
635–647 (2005).
49. Liu, K. et al. Let-7a inhibits growth and migration of breast cancer cells by
targeting HMGA1. Int. J. Oncol. 46, 2526–2534 (2015).
50. Wang, X. et al. Regulation of let-7 and its target oncogenes (Review). Oncol.
Lett. 3, 955–960 (2012).
51. Lee, Y. S. & Dutta, A. The tumor suppressor microRNA let-7 represses the
HMGA2 oncogene. Genes. Dev. 21, 1025–1030 (2007).
52. Kim, H. H. et al. HuR recruits let-7/RISC to repress c-Myc expression. Genes. Dev.
23, 1743–1748 (2009).
53. Settembre, C. et al. A lysosome-to-nucleus signalling mechanism senses and
regulates the lysosome via mTOR and TFEB. EMBO J. 31, 1095–1108 (2012).
54. Roczniak-Ferguson, A. et al. The transcription factor TFEB links
mTORC1 signaling to transcriptional control of lysosome homeostasis. Sci.
Signal. 5, ra42 (2012).
55. Marte, B. M. et al. NDF/heregulin activates MAP kinase and p70/p85 S6 kinase
during proliferation or differentiation of mammary epithelial cells. Oncogene
10, 167–175 (1995).
56. Petersen, N. H. et al. Transformation-associated changes in sphingolipid
metabolism sensitize cells to lysosomal cell death induced by inhibitors of
acid sphingomyelinase. Cancer Cell. 24, 379–393 (2013).
57. Gromova, I. et al. Immunoexpression analysis and prognostic value of BLCAP
in breast cancer. PLoS. One 7, e45967 (2012).
58. Cabezon, T. et al. Proteomic proﬁling of triple-negative breast carcinomas in
combination with a three-tier orthogonal technology approach identiﬁes
Mage-A4 as potential therapeutic target in estrogen receptor negative breast
cancer. Mol. Cell. Proteom. 12, 381–394 (2013).
59. Pfafﬂ, M. W. A new mathematical model for relative quantiﬁcation in real-time
RT-PCR. Nucleic Acids Res. 29, e45 (2001).
60. Ivascu, A. & Kubbies, M. Rapid generation of single-tumor spheroids for high-
throughput cell function and toxicity analysis. J. Biomol. Screen. 11, 922–932
(2006).
Tvingsholm et al. Oncogenesis  (2018) 7:14 Page 15 of 15
Oncogenesis
